1.Tumor-related microRNA targeting PTEN
Journal of International Oncology 2011;38(10):732-735
MicroRNAs are the endogenous non-coding RNAs that regulate gene expression by mediating gene post-transcriptional silence.Among them,miR-21,miR-17-92,miR-214,miR-26a,miR-221,miR-222and so on mainly suppress the expression of PTEN phosphohydrolase through targeting PTEN mRNA 3'-UTR.PTEN plays an important role in cell proliferation,apoptosis,migration and invasion,and its low expression will induce tumorigenesis.
2.Development process of the repair materials for hernia
Chinese Journal of Digestive Surgery 2015;14(10):816-817
Meshes or prostheses for hernia repair have been developing for half a century, while the best material is far away from being found.Although a few of disadvantages have been made up with products updating, new problems with usage have still arisen.In this review, development process of the repair materials for hernia was summarized and explored.
3.Several hot topics of clinical biochemistry
Chinese Journal of Laboratory Medicine 2014;37(1):9-12
With the rapid development of life science and relevant technology of clinical laboratory medicine,it raised higher demands for current clinical biochemistry,which is to maximize the clinical efficacy and application value under the perfect quality management system.Based on the evidence-based medicine,considering the national conditions and the new situation of medical reform,comprehensive assessment the clinical performance of new technologies and new tests,to provide more objective and reliable evidence for practical application and to guide clinical decision making,is of great significance for the rational allocation and utilization of the limited medical resources.At the same time,promoting the development of personalized medicine process gradually,trying to change the passive medical model,focusing on the disease prediction,prevention and control,taking people as the foremost,optimizing the treatment plan,and strengthening the safety and efficacy of drugs,will become hot topics of clinical biochemistry.
4.Combine library and institute of information: The development model of institute of resources-information
International Journal of Traditional Chinese Medicine 2012;34(9):812-814
This paper presents a development model of resource information institute from organic integration the institute of information and library.The all data of resources-information institute come from and serve for theoretical research,clinical practice,and scientific research of TCM.Comparing with usual research institute and library,the resource information institute has five dominant positions,which are subjects,scientific researches,resource,professionals and services.
5.The standardization process of glycosylated hemoglobin tests
Chinese Journal of Laboratory Medicine 2012;35(6):511-516
Glycohemoglobin (HbA1c) is an important indicator for assessing long-term glycemic levels and diabetic complications of blood vessels in diabetic patients.However the test methods,reagents and technological capabilities in different laboratories are various,so there are significantly differences of the results in bias.In 2010 HbA1c was included in new guidelines from ADA for diagnosing diabetes,and recommended by WHO in 2011,which promoted the standardization process of HbA1c tests.In this article we analysed and reviewed main detection methods,the international advancement of standardization,current status of the establishment of HbA1c Reference system in China and its clinical application.
6.Clinical biochemistry: review and prospect
Chinese Journal of Laboratory Medicine 2013;(1):22-24
With the rapid development of life science and bioinformatics,clinical biochemistry is in a period of vigorous development under the new situation of medical reform.The work of mutual recognition of test results was carried out smoothly,new guidelines for clinical applications were introduced in succession,testing technology was gradually improved.Automation,molecularization and omics study has become three trends in the development of clinical biochemistry,leading clinical biochemistry's development in an all-round way.In this article we reviewed the main events of clinical biochemistry in 2012,and look forward to witnessing that laboratory medicine will play a more important role in the diagnosis and treatment of diseases in 2013.
7.Effect of Solifenacin and Epalrestat combination therapy on type 2 diabetes complicated with overactive bladder
Chinese Journal of Diabetes 2017;25(5):415-419
Objective To investigate the effect of solifenacin and epalrestat combination therapy on type 2 diabetes complicated with overactive bladder (OAB).Methods A total of 80 patients with T2DM and OAB were randomly divided into three groups:control group (Con group,n=24),epalrestat group (n=29),and solifenacin combines epalrestat group (n=27).Con group was treated with conventional therapy such as routine bladder training,anti-hyperglycemic,anti-hypertensive,lipid lowering treatment,and nerve nutrition.Epalrestat group was treated with epalrestat 50 mg,3/d orally on the basis of conventional treatment.Solifenacin group was treated with solifenacin 5 mg,1/d,and epalrestat 50 mg,3/d orally.All the subjects were followed up for 12 weeks.Voiding diary,OAB self rating scale (OABSS) score,maximum urinary flow rate (Qmax),average urinary flow rate (Qave),and urine volume(VV) were recorded.Results The daily micturition frequency in 24h,times of nocturia,urgency,frequency,and urinary incontinence,and OABSS scores were lower,while Qmax,Qave,and VV were higher in solifenacin group than in Con group and epalrestat group (P<0.05).The OABSS scores were lower while VV was higher in epalrestat group than in Con group (P<0.05).The total effective rate was higher in solifenacin group than in Con group and epalrestat group (92.6% vs 69% vs 41.7%,P<0.05).Conclusion Solifenacin and epalrestat combination therapy was effective in treating patients with T2DM and OAB.
8.Clinical effect of linagliptin combined with insulin aspart 50 in treatment of hepatogenous diabetes
Journal of Clinical Hepatology 2017;33(5):928-931
Objective To investigate the clinical effect and safety of linagliptin combined with insulin aspart 50 in the treatment of hepatogenous diabetes (HD).Methods A total of 57 patients with HD who visited The People's Hospital of Liaoning Province from October 2014 to February 2016 were enrolled and randomly divided into insulin aspart 50 group (group A,28 patients) and linagliptin combined with insulin aspart 50 group (group B,29 patients).The two groups were compared in terms of blood glucose,insulin,C-peptide,glucose disposition index (DI),glycosylated hemoglobin A1c (HbA1c),glucagon,and daily insulin dose at baseline and after 12 weeks of treatment.The adverse events including hypoglycemia were observed.The paired t-test was used for comparison of continuous data within one group,and the independent-samples t test was used for comparison of continuous data between groups;the chi-square test was used for comparison of categorical data between groups.Results After 12 weeks of treatment,both groups had significant reductions in blood glucose at four time points (t =5.357-21.380,all P < 0.05) and significant increases in the insulin level at 30,60,and 120 minutes (t =2.222-6.491,all P <0.05).Compared with group A,group B had significantly lower levels of HbA1c and glucagon,daily insulin dose,and blood glucose and insulin levels at 30,60,and 120 minutes (t =3.136-15.096,all P < 0.05),as well as significantly higher DI and levels of C-peptide at four time points (t =2.994-10.813,all P < 0.05).Group A had a significantly higher incidence rate of hypoglycemia than group B (28.6% vs 3.4%,x2 =5.005,P < 0.05).Conclusion Linagliptin combined with insulin aspart 50 can effectively control blood glucose in patients with HD and has good safety.
9.Holmes-Adie syndrome with sweating abnormality (report of 1 case)
Journal of Clinical Neurology 1992;0(01):-
Objective To investigate the clinical manifestation, pathological features and pathogenesis of Holmes-Adie syndrome (HAS). Methods The clinical data of one HAS patient with sweating abnormality and combined with literatures were analysed. Results The patient had the typical characteristics of HAS, including Adie pupil, areflexia of lower limb and the symptoms of autonomic nerve dysfunction. The characteristic pupil of HAS was proved by slit lamp of ophthalmology. Cranial MRI showed lacunar infarction. A partial or total loss of neurons of the ciliary ganglion was the main pathological characteristic of HAS. Conclusions The etiology of HAS remains unclear, and has characteristic pupil finding, which was associated with autonomic nerve dysfunction to a certain extent. HAS still need to differentiate from Ross syndrome and Harlequin syndrome.
10.Clinical significance of D-dimer in rapid screening for acute aortic dissection
Jun YANG ; Shuo WANG ; Chunsheng LI
Chinese Journal of General Practitioners 2010;09(11):769-771
Objective To investigate clinical significance of D-dimer and other easily-obtained laboratory parameters in rapid screening for acute aortic dissection ( AAD). Methods Data of general health, clinical symptoms, white blood cell (WBC) count, serum levels of C-reactive protein (CRP),cardiac troponin Ⅰ (cTn Ⅰ ) and D-dimer in patients with confirmed AAD and acute coronary syndrome (ACS) were retrospectively analyzed. Significance of varied parameters in clinical diagnosis for AAD was evaluated by logistic regression model and their diagnostic values were evaluated by receiver operating characteristics (ROC) curve. Results Serum level of D-dimer increased significantly in patients with type Ⅰ AAD, as compared with that in those with type Ⅱ and type Ⅲ (P = 0. 111 and 0. 002, respectively). D-dimer, WBC and CRP all were independent risk factors for type Ⅰ AAD by logistic regression model fitted,with the largest effect of D-dimer. Analysis by ROC curve with sensitivities and specificities of serum levels of D-dimer and CRP, and WBC count also showed the same results. Conclusions Determination of serum level of D-dimer had significantly diagnostic value for AAD, and can be sued as rapid screening for it if combined with determinations of WBC and CRP.